Dr. Clay Siegall is a man of many acts thanks to his extensive educational background. He has a Ph.D in Genetics from George Washington University, and he has a B.S. in Zoology from the University of Maryland. Cancer research is one of the most demanding fields of work on the planet. There is so much to do before a cancer fighting drug ever hits the market. Who is better to understand this more so than Siegall? The guy has spent his last 20 years in this dynamic business and everything hasn’t gone as planned. Seattle Genetics is one of the more premier biotech companies that specialize in developing and commercializing antibody based-therapies. Siegall just so happens to be the president and the CEO.
“Seattle Genetics struggled in its first few years,” said Siegall. Much of the company’s capital was being depleted thanks to all of the day-to-day operations. Change was inevitable as the company brought in an all-new dynamic sales team. This team was already verses in biotechnology and cancer research. After this progressive implementation, Seattle Genetics caught its breath and the rest was history. In over the past five years, the company’s stock has nearly tripled. ADCETRIS, Seattle Genetics’ flagship drug, has brought in up to $350 million on its own. This drug is very advanced, especially when being compared to former cancer drugs. ADCETRIS is designed to seek out and to destroy cancer cells in the body while sparing the good cells. No other cancer fighting drug can duplicate this action as ADCETRIS has changed the status quo.
Siegall’s strong passion can’t be denied as he has a firm interest in saving lives. Of course, earning a comfortable living is a motivating factor, but this disease seems to hit home for him. His father suffered from cancer and to see how devastating the effects are on the body, Siegall vowed to make a difference. All in all, Dr. Clay Siegall understands what it takes to become a success, and he fully understands what it takes to fight cancer.